Both, PR-A and -B as well as PR-B alone were associated with chemosensitivity to paclitaxel (P=0.007 and P=0.022, respectively), whereby tumours with relatively high levels of receptor expression appeared less sensitive to paclitaxel compared with carcinomas with low levels of the PR (Figure 3A and B). Here, RB1 is linked to carcinoma.